Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose enzalutamide for fatigue and cognitive side effects in frail metastatic castration-resistant prostate cancer
2018-000779-33Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enzalutamide in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Change in FACIT-Fatigue subscale score at 6 weeks. Started Mar 2018; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on 2018-000779-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000779-33.